Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 2/20 | 0.67 |
| ▸ | MARS1 | P56192 | 11/20 | 0.67 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100250 | 0.90 | RPA1 (0.54) | RPA1MARS1SMPD1PPP1CALMNA | |
| SCHEMBL3092493 | 0.83 | FAAH (0.53) | RPA1MARS1LMNAMEN1MAPT | |
| SCHEMBL3088747 | 0.83 | SMPD1 (0.58) | RPA1MARS1SMPD1LMNASMN1; SMN2 | |
| SCHEMBL29687591 | 0.82 | MARS1 (0.95) | RPA1MARS1SMPD1PPP1CAL3MBTL1 | |
| SCHEMBL1514645 | 0.82 | MARS1 (0.95) | RPA1MARS1SMPD1PPP1CAL3MBTL1 | |
| SCHEMBL3099863 | 0.81 | RPA1 (0.65) | RPA1MARS1SMPD1PPP1CALMNA | |
| SCHEMBL3087783 | 0.81 | CNR1 (0.73) | — | |
| SCHEMBL3095089 | 0.81 | CNR1 (0.53) | — | |
| SCHEMBL2871062 | 0.81 | RPA1 (1.00) | RPA1MARS1SMPD1PPP1CAL3MBTL1 | |
| SCHEMBL3092456 | 0.80 | CNR1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803799-B2 | such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-09-28 | — | — | US | disclosed |
| CN-101528706-A | Pyrazole compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2009-09-09 | — | — | CN | disclosed |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | CNR2, CNR1, SELENOI | RPA1 4862/4885MARS1 3841/4885SMPD1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.